Valion Bio, Inc. Proceeds from Common Stock Issued
Valion Bio, Inc. (VBIO) reported Proceeds from Common Stock Issued of $69.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-14
- Valion Bio, Inc. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $0.00.
- Valion Bio, Inc. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $429.00K.
- Valion Bio, Inc. proceeds from issuance of common stock for the quarter ending 2024-12-31 was $0.00.
- Valion Bio, Inc. proceeds from issuance of common stock for the quarter ending 2024-09-30 was -$3.25M, a 175.32% decline year-over-year.
- Valion Bio, Inc. proceeds from issuance of common stock for fiscal 2025 was $2.34M.
- Valion Bio, Inc. proceeds from issuance of common stock for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Valion Bio, Inc. proceeds from issuance of common stock for fiscal 2023 was $8.51M.
- Valion Bio, Inc. proceeds from issuance of common stock for fiscal 2021 was $14.89M.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $69.00K 10-Q · filed 2026-08-14 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $429.00K derived: sum of 2 quarters · filed 2026-03-30 | $2.34M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | $429.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.34M 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $1.91M 10-Q · filed 2026-08-14 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$3.25M derived: sum of 2 quarters · filed 2026-03-30 | $0.00 10-K · filed 2026-03-30 | $4.38M 10-K · filed 2025-03-21 | |
| 2024-09-30 | -$3.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | $3.25M 10-Q · filed 2025-08-14 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $4.32M derived: sum of 2 quarters · filed 2025-03-21 | $4.32M derived: sum of 3 quarters · filed 2025-03-21 | $8.51M 10-K · filed 2025-03-21 | |
| 2023-09-30 | $4.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $4.32M derived: sum of 2 quarters · filed 2023-11-14 | $8.51M 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $4.19M 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $4.19M 10-Q · filed 2024-05-15 | ||||
| 2021-12-31 | $14.89M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |